Biosynex SA operates within the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biosynex SA with three other
pharmaceutical manufacturers in Europe:
Les Trois Chenes
sales of 27.34 million Euro [US$33.31 million]
(27.72 million Euro [US$33.76 million]
of which 100%
was Genetic R&D), and
Horizon Discovery Group PLC
based in the United Kingdom
(£24.07 million [US$33.30 million]
of which 53%
Sales increased substantially in 2016:
During the year ended December of 2016, sales at
Biosynex SA were 27.04 million Euro (US$32.93 million).
increase of 173.9%
versus 2015, when the company's sales were 9.87 million Euro.
This was the fifth consecutive year of sales increases at Biosynex SA
(and since 2011, sales have increased a total of 2,474%).
Sales of Sale of Goods saw an increase
255.6% in 2016, from
6.02 million Euro to 21.41 million Euro.
Not all segments of Biosynex SA experienced an increase in sales in 2016:
sales of Services fell 76.7% to 271,070.00 Euro.